For the quarter ending 2025-09-30, RIGL had -$4,873K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 27,900 | 71,059 |
| Stock-based compensation expense | 3,363 | 6,600 |
| Depreciation and amortization | 603 | 1,211 |
| Release of cost share liability | 0 | 39,981 |
| Net amortization of discount on short-term investments and term loans | 467 | 440 |
| Accounts receivable, net | 6,018 | -1,708 |
| Inventories | -188 | 6,954 |
| Prepaid and other current and non-current assets | 1,872 | 6,589 |
| Right-of-use assets | 128 | -932 |
| Accounts payable | -3,444 | 3,951 |
| Accrued compensation | 2,168 | -2,242 |
| Accrued research and development | 695 | 48 |
| Revenue reserves and refund liability | 518 | 3,062 |
| Other accrued liabilities | 350 | -1,803 |
| Lease liabilities | -81 | 946 |
| Net cash provided by operating activities | 24,031 | 29,644 |
| Maturities of short-term investments | 20,730 | 26,850 |
| Purchases of short-term investments | 53,893 | 60,678 |
| Capital expenditures | 12 | - |
| Net cash (used in) provided by investing activities | -33,175 | -33,828 |
| Net proceeds from issuance of common stock from equity plans | 4,271 | 902 |
| Net cash provided by (used in) financing activities | 4,271 | 902 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -4,873 | -3,282 |
| Cash and cash equivalents at beginning of period | 56,746 | - |
| Cash and cash equivalents at end of period | 48,591 | - |
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)